FY2026 EPS Estimate for Gain Therapeutics Lowered by Analyst

Gain Therapeutics, Inc. (NASDAQ:GANX) – Analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of Gain Therapeutics in a research note issued to investors on Thursday, May 28th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.51) per share for the year, down from their prior estimate of ($0.50). The consensus estimate for Gain Therapeutics’ current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for Gain Therapeutics’ FY2027 earnings at ($0.48) EPS.

Gain Therapeutics (NASDAQ:GANX) last announced its earnings results on Monday, May 11th. The company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). During the same quarter last year, the business earned ($0.16) earnings per share.

GANX has been the subject of a number of other reports. Oppenheimer restated an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday. Roth Mkm restated a “buy” rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Gain Therapeutics in a research note on Friday, April 10th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Gain Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $1.95 on Monday. The firm has a market cap of $83.17 million, a PE ratio of -3.36 and a beta of 0.16. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $4.34. The company has a fifty day moving average price of $1.87 and a 200 day moving average price of $2.37.

Institutional Investors Weigh In On Gain Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Marshall Wace LLP raised its holdings in shares of Gain Therapeutics by 849.3% in the 4th quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock valued at $5,353,000 after purchasing an additional 1,487,186 shares during the period. Potomac Capital Management Inc. bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at about $3,252,000. Geode Capital Management LLC raised its holdings in shares of Gain Therapeutics by 15.6% in the 4th quarter. Geode Capital Management LLC now owns 397,942 shares of the company’s stock valued at $1,282,000 after purchasing an additional 53,796 shares during the period. Jane Street Group LLC raised its holdings in shares of Gain Therapeutics by 234.5% in the 4th quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock valued at $780,000 after purchasing an additional 169,878 shares during the period. Finally, State Street Corp raised its holdings in shares of Gain Therapeutics by 72.9% in the 4th quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after purchasing an additional 66,400 shares during the period. 11.97% of the stock is owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.